Arrowhead Nanobiotechnology Subsidiaries, Calando Pharmaceuticals, Inc. and Insert Therapeutics Inc., Complete Merger

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (Nasdaq:ARWR) announced today the completion of the merger between Insert Therapeutics, Inc. and Calando Pharmaceuticals, Inc. The merger is part of a streamlining of the two companies in which Arrowhead assumed active management to increase efficiency and focus resources on bringing multiple products to the clinic as rapidly as possible. The merged company will do business under the name “Calando Pharmaceuticals, Inc.”